SEC Form 4 · accession 0001551891-26-000002
ARS Pharmaceuticals, Inc. · SPRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laura Shawver
Director
Period of report
Jun 24, 2026
Accepted (ET)
Jun 26, 2026 · 4:15 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001671858
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $10.54 | Jun 24, 2026 | A | 30,000 | A | — | Jun 23, 2036 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.